We are live on ! Find out more
NVO

Novo Nordisk

483 hedge funds and large institutions have $5.59B invested in Novo Nordisk in 2016 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 122 increasing their positions, 213 reducing their positions, and 93 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.07% less ownership

Funds ownership: 18.56%15.49% (-3.1%)

6% less funds holding

Funds holding: 513483 (-30)

23% less first-time investments, than exits

New positions opened: 72 | Existing positions closed: 93

28% less capital invested

Capital invested by funds: $7.77B → $5.59B (-$2.18B)

43% less repeat investments, than reductions

Existing positions increased: 122 | Existing positions reduced: 213

43% less funds holding in top 10

Funds holding in top 10: 148 (-6)

59% less call options, than puts

Call options by funds: $13.1M | Put options by funds: $31.9M

Holders
483
Holders Change
-30
Holders Change %
-5.85%
% of All Funds
12.05%
Holding in Top 10
8
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-42.86%
% of All Funds
0.2%
New
72
Increased
122
Reduced
213
Closed
93
Calls
$13.1M
Puts
$31.9M
Net Calls
-$18.8M
Net Calls Change
-$3.89M

NVO Hedge Fund Activity: Q4 2016 in Review

483 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2016, worth a combined $5.59B — down 28% from $7.77B a quarter earlier.

Sellers outnumbered buyers: 93 funds closed out of NVO and 72 opened new positions — a net loss of 21 holders — while 213 trimmed existing stakes and 122 added.

The largest buyer was Loomis, Sayles & Company, adding an estimated $140M. The largest seller was WCM Investment Management, cutting an estimated $335M.

  • 483 institutional investors held Novo Nordisk (NVO) as of Q4 2016, down from 513 in Q3 2016.
  • Funds reported $5.59B of Novo Nordisk stock for Q4 2016, down 28% quarter-over-quarter.
  • 72 funds opened new Novo Nordisk positions in Q4 2016 and 93 closed out, a net change of -21 holders.
  • The largest Novo Nordisk buyer in Q4 2016 was Loomis, Sayles & Company, an estimated $140M added.
  • The largest Novo Nordisk seller in Q4 2016 was WCM Investment Management, an estimated $335M sold.

Based on aggregated 13F filings for Q4 2016.